Brief: Aligos Therapeutics Q3 EPS USD -0.41
02/11/2023 21:37
Nov 2 (Reuters) - Aligos Therapeutics Q3 income from operations USD -19.071 million. * Q3 pretax profit USD -18.012 million * Q3 operating expenses USD 22.31 million * Q3 net income USD -18.041 million * Q3 EPS USD -0.41
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue